I don't mean to be repetitious--but for those who don't realize what IMC-1121B involves (made/co-licensed via DYAX technology), here's an except from Lilly:
'Ramucirumab [IMC-1121B] represents one of the largest clinical programs currently underway at Lilly. Six global Phase III trials — one each in breast, colorectal, hepatocellular and lung cancer, and two in gastric cancer — are ongoing and patient enrollment milestones have recently been achieved in both the Phase III breast and gastric (monotherapy) cancer trials.'
In a report published Wednesday, January 9, 2013, Bank of America Merrill Lynch reiterated its Buy rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $57.00 to $60.00.
BofA Merrill Lynch noted, “...Several promising late-stage pipeline assets are underappreciated, in our view, and could be transformative to LLYs growth trajectory (ramucirumab, solanezumab and the four Phase III diabetes assets - two basal insulins, empagliflozin and dulaglutide).”